Abstract

Described herein are compounds of Formula II and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as IKZF2 degraders) in treating or preventing diseases or disorders.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/541 - Non-condensed thiazines containing further heterocyclic rings
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 35/00 - Antineoplastic agents
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 487/04 - Ortho-condensed systems
• C07D 498/04 - Ortho-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

Described herein are compounds of Formulae I′ and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as IKZF2 degraders).

IPC Classes  ?

• C07D 491/20 - Spiro-condensed systems
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• C07D 471/20 - Spiro-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

Described herein are compounds or conjugates of Formula II and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).

IPC Classes  ?

• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• C07D 491/20 - Spiro-condensed systems

Abstract

Described herein are compounds of Formula (I): T-L-C and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as SMARCA2 or SMARCA4 degraders) in therapy, eg in the treatment of various types of cancer.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• C07D 471/14 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 487/10 - Spiro-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Abstract

Described herein are compounds of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., for degrading certain proteins such as p300/CBP proteins).

IPC Classes  ?

• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
• C07D 221/04 - Ortho- or peri-condensed ring systems
• C07D 471/04 - Ortho-condensed systems
• C07D 498/04 - Ortho-condensed systems

Abstract

Described herein are compounds of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., for degrading certain proteins such as p300/CBP proteins).

IPC Classes  ?

• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 491/044 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61P 35/00 - Antineoplastic agents
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

Described herein are compounds of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., for degrading certain proteins such as p300/CBP proteins).

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 419/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 471/06 - Peri-condensed systems
• C07D 498/06 - Peri-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure relates method of identifying a compound targeting a first protein and a second protein, wherein the first protein and/or the second protein are associated with a disease or disorder.

IPC Classes  ?

• G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present disclosure relates method of identifying a compound targeting a first protein and a second protein, wherein the first protein and/or the second protein are associated with a disease or disorder.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

e.g.,e.g., as cereblon-binding agents).

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 498/04 - Ortho-condensed systems
• A61K 31/4188 - 1,3-Diazoles condensed with heterocyclic ring systems, e.g. biotin, sorbinil
• A61P 35/00 - Antineoplastic agents

Abstract

e.g.,e.g., for degrading certain proteins such as CBP/p300 proteins).

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
• A61P 35/00 - Antineoplastic agents
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
• C07D 498/04 - Ortho-condensed systems

Abstract

Described herein are compounds of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as SMARCA2 or SMARCA4 degraders).

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07D 487/10 - Spiro-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61P 35/00 - Antineoplastic agents
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/527 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim spiro-condensed

Abstract

Described herein are compounds of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., for degrading certain proteins such as STAT3).

IPC Classes  ?

• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

Described herein are compounds of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., for degrading certain proteins such as p300/CBP proteins).

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
• C07D 498/04 - Ortho-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61P 35/00 - Antineoplastic agents

Abstract

e.g.,e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).

IPC Classes  ?

• C07D 491/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents

Abstract

Described herein are compounds of Formula II or conjugates of Formula II' and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents or degraders for certain proteins).

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/45 - Non-condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine

Abstract

Described herein are compounds and conjugates of Formula II and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as SMARCA2 or SMARCA4 inhibitors or degraders).

IPC Classes  ?

• C07D 471/16 - Peri-condensed systems
• C07D 471/20 - Spiro-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 491/20 - Spiro-condensed systems
• A61P 35/00 - Antineoplastic agents
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Abstract

Described herein are compounds of Formula II and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as SMARCA2 or SMARCA4 degraders).

IPC Classes  ?

• C07D 471/14 - Ortho-condensed systems
• C07D 471/20 - Spiro-condensed systems
• C07D 487/04 - Ortho-condensed systems
• A61P 35/00 - Antineoplastic agents
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Abstract

Described herein are compounds or conjugates of of Formulae II and I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).

IPC Classes  ?

• C07D 491/147 - Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

Described herein are compounds and conjugates of Formulae I and II and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents and bifunctional degraders for certain proteins).

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• C07D 498/04 - Ortho-condensed systems
• A61K 31/4462 - Non-condensed piperidines, e.g. piperocaine only substituted in position 3
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

Abstract

Described herein are compounds of Formula I and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).

IPC Classes  ?

• C07D 498/14 - Ortho-condensed systems
• C07D 498/10 - Spiro-condensed systems
• C07D 491/20 - Spiro-condensed systems
• C07D 471/10 - Spiro-condensed systems
• A61P 35/00 - Antineoplastic agents
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems

Abstract

Described herein are compounds of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as estrogen receptor degraders).

IPC Classes  ?

• C07D 498/20 - Spiro-condensed systems
• C07D 498/14 - Ortho-condensed systems
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• A61P 35/00 - Antineoplastic agents

Abstract

Described herein are compounds or conjugates of Formulae II and I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).

IPC Classes  ?

• C07D 498/04 - Ortho-condensed systems
• C07D 498/14 - Ortho-condensed systems
• A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
• A61P 35/00 - Antineoplastic agents

Abstract

Described herein are compounds of Formula I and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).

IPC Classes  ?

• C07D 498/14 - Ortho-condensed systems
• C07D 498/10 - Spiro-condensed systems
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• A61P 35/00 - Antineoplastic agents

Abstract

Described herein are compounds of Formula (I) and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).

IPC Classes  ?

• C07D 498/14 - Ortho-condensed systems
• C07D 498/20 - Spiro-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• A61P 35/00 - Antineoplastic agents

Abstract

Described herein are compounds of Formulae I' and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as IKZF2 degraders).

IPC Classes  ?

• C07D 491/20 - Spiro-condensed systems
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• A61P 35/00 - Antineoplastic agents

Abstract

Described herein are compounds of Formulae I' and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as IKZF2 degraders).

IPC Classes  ?

• C07D 491/20 - Spiro-condensed systems
• C07D 471/20 - Spiro-condensed systems
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• A61P 35/00 - Antineoplastic agents

Abstract

e.ge.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).

IPC Classes  ?

• C07D 471/20 - Spiro-condensed systems
• C07D 491/20 - Spiro-condensed systems
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• A61P 5/00 - Drugs for disorders of the endocrine system
• A61P 35/00 - Antineoplastic agents

Abstract

Described herein are compounds of Formula II and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as IKZF2 degraders) in treating or preventing diseases or disorders.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 495/02 - Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
• A61P 35/00 - Antineoplastic agents
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• C07D 487/08 - Bridged systems

Goods & Services

Downloadable computer software for use in the field of drug discovery, screenings, and pharmaceuticals; downloadable computer software for use to diagnose medical conditions, to prescribe medical treatment and prescriptions, to design clinical trials and forecast clinical trial results, to search for clinical trial patients, to analyze medical images, to analyze data, and to develop pharmaceutical products and chemical compounds; downloadable computer software for use in collecting, analyzing, reporting, and tracking data and information in the fields of drug discovery and development, genetics, genomics, biology, biochemistry, clinical trial management and patient engagement. Drug discovery services; DNA and protein screening for scientific research purposes; platform as a service (PAAS) featuring computer software platforms for use in the field of drug discovery, screenings, and pharmaceuticals; scientific and technological services and research and design relating thereto; analysis of technical data by computers; pharmaceutical drug discovery services; pharmaceutical and biotechnology research and development services; drug use discovery services; design and development of pharmaceutical preparations and medicines; research and development in the field of drug discovery; conducting scientific and pharmaceutical research and data analysis to screen for and identify molecular interactions, compounds and detect toxicity; providing scientific, pharmaceutical and agrochemical database research services; scientific and pharmaceutical artificial intelligence research services to identify molecules and compounds for drug discovery and chemical development; bioinformatics services, namely, using the combination of biology, computer science, information engineering, mathematics and statistics to analyze and interpret biological data; computer assisted molecule design; identification of biological targets, networks and pathways; biological research and analysis; pharmaceutical research and development services; computer aided diagnostic and screening services for scientific research purposes; contract research services in support of scientific research and development of pharmaceutical preparations; software as a service (SaaS) featuring software to diagnose medical conditions, to prescribe medical treatment and prescriptions, to design clinical trials and forecast clinical trial results, to search for clinical trial patients, to analyze medical images, to analyze data, and to develop pharmaceutical products and chemical compounds; software as a service for collecting, analyzing, reporting, and tracking data and information in the fields of drug discovery and development, genetics, genomics, biology, biochemistry; software as a service for collecting, analyzing, reporting, and tracking data and information in the fields of clinical trial management and patient engagement.

Goods & Services

(1) Downloadable computer software for use in the field of drug discovery, screenings, and pharmaceuticals; downloadable computer software for use to diagnose medical conditions, to prescribe medical treatment and prescriptions, to design clinical trials and forecast clinical trial results, to search for clinical trial patients, to analyze medical images, to analyze data, and to develop pharmaceutical products and chemical compounds; downloadable computer software for use in collecting, analyzing, reporting, and tracking data and information in the fields of drug discovery and development, genetics, genomics, biology, biochemistry, clinical trial management and patient engagement. (1) Drug discovery services; DNA and protein screening for scientific research purposes; platform as a service (PAAS) featuring computer software platforms to diagnose medical conditions, to prescribe medical treatment and prescriptions, to design clinical trials and forecast clinical trial results, to search for clinical trial patients, to analyze medical images, to analyze data, and to develop pharmaceutical products and chemical compounds; platform as a service (PAAS) feature computer software platforms for collecting, analyzing, reporting, and tracking data and information in the fields of drug discovery and development, genetics, genomics, biology, biochemistry; platform as a service (PAAS) featuring computer software platforms for collecting, analyzing, reporting, and tracking data and information in the fields of clinical trial management and patient engagement; scientific and technological research and industrial design in the fields of pharmaceuticals, clinical trials, biological therapeutic research services, and biomedical research services; analysis of technical data by computers in the fields of pharmaceuticals, clinical trials, biological therapeutic research services, and biomedical research services; pharmaceutical drug discovery services; pharmaceutical and biotechnology research and development services in the fields of pharmaceuticals, clinical trials, biological therapeutic research services, and biomedical research services; drug use discovery services; design and development of pharmaceutical preparations and medicines; research and development in the field of drug discovery; conducting scientific and pharmaceutical research and data analysis to screen for and identify molecular interactions, compounds and detect toxicity; providing scientific, pharmaceutical and agrochemical database research services; scientific and pharmaceutical artificial intelligence research services to identify molecules and compounds for drug discovery and chemical development; bioinformatics services, namely, using the combination of biology, computer science, information engineering, mathematics and statistics to analyze and interpret biological data; computer assisted molecule design; identification of biological targets, networks and pathways; biological research and analysis; pharmaceutical research and development services; computer aided diagnostic and drug screening services for scientific research purposes in the fields of pharmaceuticals, clinical trials, biological therapeutic research services, and biomedical research services; contract research services in support of scientific research and development of pharmaceutical preparations; software as a service (SaaS) featuring software to diagnose medical conditions, to prescribe medical treatment and prescriptions, to design clinical trials and forecast clinical trial results, to search for clinical trial patients, to analyze medical images, to analyze data, and to develop pharmaceutical products and chemical compounds; software as a service for collecting, analyzing, reporting, and tracking data and information in the fields of drug discovery and development, genetics, genomics, biology, biochemistry; software as a service for collecting, analyzing, reporting, and tracking data and information in the fields of clinical trial management and patient engagement.

Goods & Services

Downloadable computer software for drug discovery, screenings, and providing pharmaceuticals; downloadable computer software for use to diagnose medical conditions, to prescribe medical treatment and prescriptions, to design clinical trials and forecast clinical trial results, to search for clinical trial patients, to analyze medical images, to analyze data, and to develop pharmaceutical products and chemical compounds; downloadable computer software for collecting, analyzing, reporting, and tracking data and information in the fields of drug discovery and development, genetics, genomics, biology, biochemistry, clinical trial management and patient engagement Drug discovery services; DNA and protein screening for scientific research purposes; Platform as a service (PAAS) featuring computer software platforms for drug discovery, screenings, and providing pharmaceuticals; Scientific and technological services and research and design, namely, research and design in the field of drug discovery and DNA and protein screening; Scientific research and development in the field of analysis of technical data by computers; pharmaceutical drug discovery services; research and development in the pharmaceutical and biotechnology fields; drug discovery services and research and development in the pharmaceutical drug use field; design and development of pharmaceutical preparations and medicines; scientific research and development in the field of drug discovery; scientific research and development in the nature of conducting scientific and pharmaceutical research and data analysis to screen for and identify molecular interactions, compounds and detect toxicity; providing scientific, pharmaceutical and agrochemical database research services; scientific research and development in the nature of scientific and pharmaceutical artificial intelligence research services to identify molecules and compounds for drug discovery and chemical development; scientific research and development in the nature of bioinformatics services for using the combination of biology, computer science, information engineering, mathematics and statistics to analyze and interpret biological data; scientific research and development in the nature of computer assisted molecule design; scientific research and development in the nature of identification of biological targets, networks and pathways; biological research and analysis; pharmaceutical research and development services; computer aided diagnostic and DNA and protein screening services for scientific research purposes; scientific research and development in the nature of contract research services in support of scientific research and development of pharmaceutical preparations; Software as a service (SaaS) services featuring software to diagnose medical conditions, to prescribe medical treatment and prescriptions, to design clinical trials and forecast clinical trial results, to search for clinical trial patients, to analyze medical images, to analyze data, and to develop pharmaceutical products and chemical compounds; Software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the fields of drug discovery and development, genetics, genomics, biology, biochemistry; Software as a service (SAAS) services featuring software for collecting, analyzing, reporting, and tracking data and information in the fields of clinical trial management and patient engagement

IPC Classes  ?

• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• C07D 498/14 - Ortho-condensed systems
• C07D 498/20 - Spiro-condensed systems